Business Daily Media

Connext Successfully Administers First Dose of CNT201 for Dupuytren's Contracture

  • Written by PR Newswire

World's First Genetically Recombinant Collagenase Therapeutics (CNT201) Begins Clinical Trials in Australia

SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients.

Dupuytren's contracture is a debilitating condition characterized by the fibrosis of the fascia between the skin and tendons of the palm due to collagen buildup, causing fingers to become permanently bent and significantly impairing patients' quality of life. Currently, there is no fundamental cure for this condition. Treatments primarily involve surgical interventions like fasciectomy to alleviate symptoms, although non-surgical methods, such as localized injections of collagenase, have shown high patient satisfaction.

It has received IND approval for Phase 1/2 clinical trials from the U.S. FDA and recently completed the Clinical Trial Notification (CTN) process in Australia. The ongoing clinical trial in Australia represents the Phase 1 part of the Phase 1/2 trial, conducted across three hospitals. The trial involves single administrations of four escalating dose levels in patients with Dupuytren's contracture, followed by a four-week evaluation period to assess safety, tolerability, efficacy, pharmacokinetics, and immunogenicity. Connext plans to secure proof-of-concept (PoC) data by mid-next year and determine the optimal dose for Phase 2, with the aim to commence the Phase 2 trial in the latter half of the year.

Connext CEO Woojong Lee remarked, "This first administration marks a significant milestone, offering new hope to patients suffering from Dupuytren's contracture. We are dedicated to developing a safer and more effective treatment to improve their quality of life."

Connext successfully raised a Series B investment at the end of last year and was selected for the Scale-Up TIPS program, enabling the initiation of global clinical trials for Dupuytren's contracture. The company is simultaneously advancing the development of additional indications, including Peyronie's disease and cellulite.

Media Contact:Sangho Lee(Communication)+82-10-8829-4694Sangho.lee@connext.co.kr[1]

References

  1. ^ Sangho.lee@connext.co.kr (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/4471232_AE71232_0


Start your own business with Shopify


It’s a tough market for renters – here’s how to make the most of your rental

Licensed real estate agent and proptech expert, Scott Shepherd from PropertyMe shares his top tips from over two decades in the industry The rate...

Property

How to Sharpen Your App Development Skills

Mobile application development is a skill that you should take seriously. It's not the easiest task in the world, and it takes more than just techni...

Business Training

FIVE REASONS WHY LEEDS & YORKSHIRE SHOULD BE ON YOUR INVESTMENT RADAR

London, Manchester, Birmingham – these are the UK cities which tend to be the most famous in terms of commercial and business investment. However...

Property

Why you need an Australian digital marketing agency

When you're looking to grow your business, hiring a digital marketing agency can be a great way to get started before hiring in-house. You can also ...

Business Training

How much is the rent in Brisbane?

If you’re looking at renting an apartment or house in Brisbane, one of the first questions you probably have is how much it is going to cost. Rent...

Property

Joust Marketplace Unleashes Game-Changing Joust Connect function

Anny Le Wilson Australia’s leading online home loans marketplace, Joust.com.au, has launched a game changing solution for the country’s mortg...

Property